Share this article on:

Mitochondrial dysfunction following perinatal exposure to nucleoside analogues

Blanche, Stéphanea; Tardieu, Marcb; Benhammou, Valériec; Warszawski, Josianec; Rustin, Pierred

doi: 10.1097/01.aids.0000242814.42344.77
Opinion Piece

From the aHopital Necker Enfants-Malades, Assistance Subligne-Hopitaux de Paris et EA 3620 Université Paris 5, France

bPaediatric Neurology Service, Hopital Bicêtre and Inserm EMI 01 09, France

cINSERM U569, Hopital Bicêtre, France

dINSERM U676, Hopital Robert Debré and Université of Paris 7, Paris, France.

Received 21 December, 2005

Accepted 5 April, 2006

Correspondence to Dr S. Blanche, Unité d'Immunologie Hématologie pédiatrique, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015 Paris, France. E-mail:

Antiretroviral drugs given during pregnancy and immediately after birth are extraordinarily effective at preventing mother-to-child transmission of HIV-1: the transmission rate is dramatically decreased from 15–20% to less than 1%, at least for women intensively managed with potent antiretroviral therapy [1,2]. Current recommendations are now based on antiretroviral combinations, mostly including at least two nucleoside analogues (NA). Because NA can cross the placenta and can interact with human DNA, fetal tolerance of these drugs used during pregnancy should be carefully assessed [3,4]. Mitochondrial toxicity in adults has been the subject of substantial attention for some years [5]. There is no obvious reason why the fetus and newborn, often exposed for many months, should escape any such effects.

Back to Top | Article Outline

Tolerance data from the initial randomized study ATCG076–ANRS024

Although zidovudine was already known to have an effect on mitochondria when the ATCG076–ANRS024 protocol was designed [6], it was considered to occur only during prolonged treatment and no specific marker was included [1]. The only toxicity formally demonstrated in this zidovudine versus placebo-controlled trial was a transient moderate anaemia of unknown mechanism [1,7]. A detailed neurocognitive analysis was performed on a small subgroup of children followed until 36 months of age and no difference was observed between the group exposed to zidovudine and the unexposed controls [8].

Back to Top | Article Outline

Primate model of mitochondrial toxicity after in-utero exposure

Several experiments performed by Miriam Poirier's group with pregnant patas monkeys have clearly shown that a human-equivalent dose of zidovudine, alone or in combination with lamivudine, leads to multiorgan mitochondrial injury in newborn animals. Mitochondrial dysfunction was demonstrated in various tissues and with variable severity through morphological damage detected by electron microscopy, OXPHOS enzyme activity alterations, zidovudine incorporation into mitochondrial DNA (mtDNA), depletion in mtDNA quantity (shown by Slot blot), and degradation of mtDNA (shown by Southern blot) [9–12]. The reversibility and clinical significance of these biological findings were not known, but more recently, persistent mitochondrial dysfunction, at least in cardiac tissues, was demonstrated after perinatal exposure in the same animal model. Monkeys perinatally exposed to various NA regimens showed extensive mitochondrial damage at 1 year of age, with clusters of mitochondria in the heart having apparently similar damage as revealed by electron microscopy [13]. Interestingly, OXPHOS activity assays were normal, and presumably these assays are not sensitive enough to detect these clusters. In contrast to what is observed at birth, mtDNA quantity was increased, suggesting a recovery process and mitochondrial proliferation.

Back to Top | Article Outline

Tolerance data from epidemiological cohorts

Observations suggestive of possible mitochondrial toxicity in children perinatally exposed to NA originated from epidemiological cohorts of children born to HIV-infected mothers and from anecdotal case reports. The main limitation of epidemiological studies is that comparison between exposed and unexposed children are uncontrolled and necessarily ‘historical’. The vast majority of unexposed children were born before 1994, whereas exposed children were born after this date. In addition, specific control groups for biological studies based on children born to uninfected mothers do not exclude potential counfounding bias linked to the HIV infection status of the mother.

Back to Top | Article Outline


Following the first description of symptomatic lactic acidosis in a child while receiving prophylactic treatment for HIV [14], several reports suggested that an important number of infants perinatally exposed to NA presented hyperlactataemia during the first few weeks or months of life [15–17]. Potential artefacts in lactate measurement were excluded in a recent controlled study showing that lactate levels were significantly higher during the first month of life in NA-exposed children than in controls. In contrast, a recent study in the Ivory Coast did not show any difference in lactate level between controls and children exposed to short-term zidovudine/lamivudine prophylaxis or to nevirapine [18], suggesting that hyperlactataemia could be linked to the level and/or duration of NA exposure. The long-term consequences of this hyperlactataemia, whether asymptomatic or symptomatic, are not known. Although transient mitochondrial injury, lasting several weeks, may have only minor clinical consequences in the muscle or liver, the potential impact in the brain needs careful evaluation.

Back to Top | Article Outline

Other biological markers of mitochondrial dysfunction at birth in humans

Three studies have described biological evidence of mitochondrial dysfunction in asymptomatic children exposed to zidovudine alone or in combination with lamivudine [19–21]. All three showed that exposed children had significantly lower levels of mtDNA in their peripheral blood lymphocytes at birth than unexposed children. In one of these studies, this difference persisted at 1 year of age [22]. Moreover, mtDNA levels were lower in the control group of untreated children born to HIV-infected mothers than in children born to uninfected mothers [19]. Depletion of mtDNA was also observed in the placenta and in the cells of the umbilical cord [20] Finally, abnormalities in mitochondrial ultrastructure, as assessed by electron microscopy, were found to be more frequent in the endothelial cells of the umbilical cord in exposed groups [21]. Studies on mtDNA quantification raised the hope that a simple non-invasive tool for the measurement of mitochondrial dysfunction could be developed. However, in addition to the potential methodological problems, it has been suggested that peripheral blood lymphocytes are not the cells most sensitive to this toxicity and that this marker is not currently suitable for routine use [23]. Discordant unpublished results have subsequently been obtained with this variable. Moreover, mtDNA depletion does not necessarily reflect a clinically detectable pathological process because the thresholds of depletion associated with clinically relevant cellular distress are unknown. In addition, mtDNA depletion is certainly not the only mechanism of NA-induced toxicity.

Back to Top | Article Outline

Neurological symptoms and persistent mitochondrial dysfunction in uninfected children

Full-blown mitochondrial neurological disease was first observed in a tolerance trial of a zidovudine/lamivudine combination during pregnancy [24,25]. The search for similar neurological syndromes associated with persistent mitochondrial dysfunction was then extended to all the 5000 HIV-uninfected children of the French national cohort [26]. After a complex stepwise screening of 150 files of children presenting neurological symptoms of unknown origin, expert groups identified 21 cases as being ‘certainly’ or ‘probably’ caused by mitochondrial dysfunction, according to diagnostic criteria similar to those for constitutional mitochondrial diseases [27,28]. The main clinical symptoms were seizures, cognitive delay, motor dysfunction, nystagmus or severe malaise. The mitochondrial origin of the symptoms was established based on profound OXPHOS deficiency and/or a severely disturbed histological pattern. Similar symptomatology, persistent hyperlactatemia and several histological images of abnormal mitochondria led to the notion of ‘probable’ mitochondrial dsyfunction despite normal or unknown OXPHOS activities. No mtDNA depletion was observed by Southern blot. All the affected children had been exposed to NA, with an incidence in this NA-exposed group of 0.3%, higher than the expected incidence of 0.01% reported for two Northern European general populations using very similar diagnostic criteria [29,30]. However, the neurological symptoms of several children remained unexplained and there were no signs indicative of mitochondrial dysfunction. Other physiopathological processes were considered, together with the difficulty in demonstrating a brain mitochondrial dysfunction, transient or persistent.

Back to Top | Article Outline

Absence of mitochondrial symptoms in other similar cohorts

The publication of these observations led to controversy, with several articles concluded that no similar cases were present in other cohorts. Some analyses quickly followed publication of the first alert [31,32] but were too rapid to be compatible with the long and complex work of investigating diverse, multifactorial and non-specific symptoms sometimes presented by HIV-1-exposed but uninfected children with neurological symptoms. A more structured analysis of five American cohorts, focusing exclusively on retrospective analysis of the medical files of children who had died, showed that none of the 223 deaths among more than 20 000 children born to HIV-seropositive women could be unambiguously attributed to a mitochondrial disease [33]. This analysis is often wrongly cited as the definitive proof of safety, affirming that tens of thousands children have been correctly screened, but this is not the case. To date, only 2 of the 21 children identified in the French cohort have died; the issue is the identification of mitochondria-related morbidity rather than mortality. More recently, two cohorts listed all the symptoms observed in uninfected children: the WITS cohort presented an analysis of the symptoms of 955 children not infected with HIV but indicated that the analysis did not take into account possible symptoms of toxicity [34]; the European ECS cohort did not report any symptom suggestive of a mitochondrial disease in more than 2000 HIV-uninfected children, half of them having been perinatally exposed to NA [35]. The very low rate of identified events of all types – including those normally expected in the general population – strongly suggested insufficient sensitivity to adverse events. These analyses are, therefore, not comparable with ours and the results obtained cannot be considered to be truly contradictory of what we observed in French cohort.

Outside these cohorts, at least two cases of severe neurological symptoms and mitochondrial dysfunction have been reported recently [36,37]. In both cases, neurological symptoms were early and severe, and mitochondrial dysfunction unambiguous. Interestingly, mtDNA was severely depleted both, in contrast with the observations in France for older children. A 5-year follow-up of one child revealed persistent but stable cognitive delay. Since the first publications, several further cases of persistent mitochondrial dysfunction have also been identified in the French cohort.

Back to Top | Article Outline

Non neurological mitochondrial disorders?

In a specific study, echocardiographic data for zidovudine-exposed children showed no significant cardiac perturbation [22]. However, the same group recently presented preliminary data suggesting that findings could be different in children exposed to antiretroviral drug combinations [38].

Other symptoms or biological disturbances have been observed in newborns and infants exposed to antiretroviral drugs [23,39]. The most convincing is certainly the long-lasting, mild, but significant inhibition of haematopoiesis, similarly observed in two independent cohorts [40–42]. However, there is currently no evidence of this intriguing persistent disturbance being of mitochondrial origin.

Back to Top | Article Outline

Diagnostic difficulties for mitochondrial toxicity in children

Mitochondrial dysfunction remains difficult to establish in humans in clinical practice [27,28,43]. The clinical symptoms are extremely diverse, involve various organs and are far from being specific. In the particular context of maternal HIV infection, the first step is to eliminate other possible causes of neurological problems, such as maternal intravenous drug use, prematurity and other infections. Simple biochemical findings, such as true hyperlactataemia and also abnormal transaminases, lipase, creatinine phosphokinases and lactate dehydrogenases may suggest mitochondrial dysfunction. However all these features are non-specific and, more confusingly, can be normal despite genuine mitochondrial dysfunction. Magnetic resonance imaging of the brain may also provide additional non-specific information regarding diffuse hypersignal in the supratentorial white matter or brainstem [44]. The diagnostic gold standard remains the demonstration of OXPHOS deficiency and/or the observation of major abnormalities of mitochondrial structure (histochemical or electron microscopy studies). In cases of significant OXPHOS perturbation or abnormal mitochondrial images, specific mutations associated with constitutional diseases can be sought. In the specific context of potential NA toxicity, mtDNA quantification is also required for complete analysis. With few exceptions, skeletal muscle tissue is analysed, and this necessitates the aggressive procedure of a muscle biopsy. However the diagnosis, even for muscle, remains difficult because assaying activities of the respiratory chain complex is not straightforward; specific histological signs in children can be subtle, with the classic red ragged fibre appearance much less frequently than observed in adults; and techniques for measuring the depletion of mtDNA (if involved) in tissues have not been standardized. Moreover, normal OXPHOS activities do not exclude the diagnosis of mitochondrial dysfunction because the muscle is not necessarily the target organ. As well-described elsewhere for constitutional diseases and applied here, a diagnostic probability scale can be used (with levels of ‘established’, ‘probable’, ‘possible’).

Back to Top | Article Outline


The physiopathological mechanisms underlying this transient or persistent mitochondrial dysfunction following a relatively short period of NA exposure (several weeks to several months) are unknown. According to current knowledge, there are various potential targets for NA in mitochondria [45–47]. The most frequently cited is mitochondrial gamma-polymerase, and its inhibition by NA presumably results in mtDNA depletion. This inhibition is in principle reversible as long as some mtDNA is still present in the cell. Any persistent dysfunction must, therefore, be the consequence of one or more other mechanisms. A transitorily impaired respiratory chain activity would be predicted to result from any significant mtDNA depletion. This would, in turn, favour overproduction of superoxides by the respiratory chain. Because of their high mutagenic potential, these reactive species may then irreversibly and randomly alter mtDNA. Irreversible mtDNA alterations might also result from impaired proof-reading activity of the mitochondrial gamma-polymerase triggered by NA.

One of the potential alternative targets suggested for zidovudine is the adenylate carrier, involved in ADP/ATP exchange across the mitochondrial inner membrane [48], as blockade of the phosphorylation step of the respiratory process has been shown to produce more toxic superoxides than any other type of respiratory chain impairment [49].

Finally, inhibition by zidovudine of the deoxynucleotide carrier on the inner mitochondrial membrane may impair mtDNA synthesis by reducing or unbalancing uptake of dNTP [50–52]. Recent descriptions of inherited deficiency of the thymidine phosphorylase report that either mtDNA depletion or a shortage of one species of nucleotide necessary for mtDNA synthesis in the mitochondrial matrix may result in inappropriate insertion of an alternative nucleotide in the place of the predicted nucleotide [53]. Any of these hypotheses that involve irreversible and randomly distributed mtDNA mutations are compatible with the apparently discordant results observed: mtDNA quantification data indicate normalization after the marked reduction following exposure, despite persisting signs of mitochondrial dysfunction such as OXPHOS deficiency. It remains to be determined whether there is any such qualitative damage of mtDNA in NA-exposed children.

Although a significant amount of work as been devoted to the impairment of mitochondrial function and mtDNA replication machinery by NA, we are still far from understanding the many potential interactions between these drugs and the various reactions of the nucleotide and nucleoside pathways. At a pharmacological level, we know little about the fetal distribution of the various NA. A recent comparative study indicated that most nucleoside reverse transcriptase inhibitors cross the placenta by simple diffusion and are concentrated in the amniotic fluid, probably through fetal urinary excretion [54]. The efficacy or toxicity of nucleoside reverse transcriptase inhibitors may vary according to placental transfer. There may be interindividual variability in genetic susceptibility for any toxicity that is related to NA pharmacology and/or mitochondria-related genes. A recent study in adults suffering from NA-induced neuropathy suggested a specific suceptibility for some mitochondria haplotypes [55].

Back to Top | Article Outline


Despite many unresolved physiopathological questions, there are coherent experimental and clinical arguments for the existence of mitochondrial toxicity following perinatal exposure to zidovudine, alone or in combination with lamivudine. This effect may be transitory or persistent. Although, the clinical significance of the various biological and/or histopathological mitochondrial anomalies found at birth in NA-exposed animals or children has not been formally established, the high incidence of mitochondrial neurological diseases observed in the French cohort has not been contradicted to date in other cohorts. All data concerning potential toxicity must be balanced against the well-proven benefit of the drugs, but also with a view to possible alternative therapeutics. Given the increasing number of antiretroviral drugs available, a comparative evaluation is required to identify the least toxic therapeutic strategies.

Sponsorship: This work is supported by Agence Nationale de Recherche sur le Sida (ANRS), Paris, France.

Back to Top | Article Outline


1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173–1180.
2. Abrams EJ. Prevention of mother-to-child transmission of HIV: successes, controversies and critical questions. AIDS Rev 2004; 6:131–143.
3. Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues: a survey. Antiviral Res 2001; 49:55–74.
4. Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199:151–161.
5. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005; 10(Suppl 2):M47–M52.
6. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322:1098–1105.
7. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, et al. Safety of the maternal–infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998; 12:1805–1813.
8. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281:151–157.
9. Poirier MC, Patterson TA, Slikker W Jr, Olivero OA. Incorporation of 3′-azido-3′-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. J Acquir Immune Defic Syndr 1999; 22:477–483.
10. Ewings EL, Gerschenson M, St Claire MC, Nagashima K, Skopets B, Harbaugh SW, et al. Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J Acquir Immune Defic Syndr 2000; 24:100–105.
11. Gerschenson M, Erhart SW, Paik CY, St Claire MC, Nagashima K, Skopets B, et al. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Hum Retroviruses 2000; 16:635–644.
12. Gerschenson M, Nguyen V, Ewings EL, Ceresa A, Shaw JA, St Claire MC, et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004; 20:91–100.
13. Divi RL, Leonard SL, Kuo MM, Walker BL, Orozco CC, St Claire MC, et al. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc Toxicol 2005; 5:333–346.
14. Scalfaro P, Chesaux JJ, Buchwalder PA, Biollaz J, Micheli JL. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 1998; 24:247–250.
15. Giaquinto C, De Romeo A, Giacomet V, Rampon O, Ruga E, Burlina A, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15:1074–1075.
16. Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22:782–789.
17. Noguera A, Fortuny C, Munoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004; 114:e598–e603.
18. Ekouévi DK, Touré R, Bequet L, Rouet F, Viho I, Tonwe-Gold B, et al. Hyperlactatemia in neonates exposed peripartum to a short course of antiretrovirals to prevent mother-to-child transmission of HIV-1. Pediatrics 2006; in press.
19. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33:175–183.
20. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-patient women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J AIDS 2003; 32:370–374.
21. Divi RL, Walker VE, Wade NA, Nagashima K, Seilkop SK, Adams ME, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004; 18:1013–1021.
22. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 2000; 343:759–766.
23. Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004; 9:849–863.
24. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, et al. Lamivudine–zidovudine combination for prevention of maternal–infant transmission of HIV-1. JAMA 2001; 285:2083–2093.
25. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084–1089.
26. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17:1769–1785.
27. Munnich A, Rustin P. Clinical spectrum and diagnosis of mitochondrial disorders. Am J Med Genet 2001; 106:4–17.
28. Schmiedel J, Jackson S, Schafer J, Reichmann H. Mitochondrial cytopathies. J Neurol 2003; 250:267–277.
29. Uusimaa J, Remes AM, Rantala H, Vainionpaa L, Herva R, Vuopala K, et al. Childhood encephalopathies and myopathies: a prospective study in a defined population to assess the frequency of mitochondrial disorders. Pediatrics 2000; 105:598–603.
30. Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA anbormalities. Ann Neurol 2001; 49:377–383.
31. Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, Lampe M, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci 2000; 918:212–221.
32. Lindegren ML, Rhodes P, Gordon L, Fleming P. Perinatal Safety Review Working Group; State and Local Health Department HIV/AIDS Surveillance Programs. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000; 918:222–235.
33. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J AIDS 2000; 25:261–268.
34. Paul ME, Chantry CJ, Read JS, Frederick MM, Lu M, Pitt J, et al. Morbidity and mortality during the first two years of life among uninfected children born to human immunodeficiency virus type 1-infected women: the women and infants transmission study. Pediatr Infect Dis J 2005; 24:46–56.
35. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:380–387.
36. Cooper ER, DiMauro S, Sullivan M, Jones-Eaves D, Kay L, Moloney C, et al. Biopsy-confirmed mitochondrial dysfunction in an HIV-exposed infant whose mother received combination antiretrovirals during the last 6 weeks of pregnancy. XV International Conference on AIDS. Bangkok, July 2004 [abstract TuPeB4394].
37. Tovo PA, Chiapello N, Gabiano C, Zeviani M, Spada M. Zidovudine administration during pregnancy and mitochondrial disease in the offspring. Antivir Ther 2005; 10:697–699.
38. Lipshultz SE, Shearer WT, Rich K, Thompson B, Cheng I, Hamon T, et al. Antiretroviral therapy-associated cardiotoxicity in uninfected but ART-exposed infants born to HIV infected women: the prospective NHLB1 CHAART-1 Study. Ninth International Conference on Environmental Mutagens. San Francisco, September 2005 [abstract 28].
39. Landreau-Mascaro A, Barret B, Mayaux MJ, Tardieu M, Blanche S, for the French Perinatal Cohort Study Group. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002; 359:583–584.
40. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S, for the Enquête Périnatale Française Study Group. Perinatal antiretroviral treatment and hematopoiesis in HIV-unifected infants. AIDS 2003; 17:2053–2061.
41. European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers. AIDS 2004; 18:2009–2017.
42. Bunders M, Thorne C, Newell ML, for the European Collaborative Study. Maternal and infant factors and lymphocyte, CD4 and CD8 counts in uninfected children of HIV-1-infected mothers. AIDS 2005; 19:1071–1079.
43. Chretien D, Rustin P. Mitochondrial oxidative phosphorylation: pitfalls and tips in measuring and interpreting enzyme activities. J Inherit Metab Dis 2003; 26:189–198.
44. Tardieu M, Brunelle F, Raybaud C, Ball W, Barret B, Pautard B, et al. Cerebral MR imaging in uninfected children born to HIV-seropositive mothers and perinatally exposed to zidovudine. Am J Neuroradiol 2005; 26:695–701.
45. Barile M, Valenti D, Quagliariello E, Passarella S. Mitochondria as cell targets of AZT (zidovudine). Gen Pharmacol 1998; 31:531–538.
46. Lewis W. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy. Antivir Ther 2005; 10(Suppl 2):M13–M27.
47. Rustin P. Mitochondrial dysfunction in HIV infection: an overview of pathogenesis. J HIV Ther 2001; 6:4–12.
48. Valenti D, Barile M, Passarella S. AZT inhibition of the ADP/ATP antiport in isolated rat heart mitochondria. Int J Mol Med 2000; 6:93–96.
49. Geromel V, Kadhom N, Cebalos-Picot I, Ouari O, Polidori A, Munnich A, et al. Superoxide-induced massive apoptosis in cultured skin fibroblasts harboring the neurogenic ataxia retinitis pigmentosa (NARP) mutation in the ATPase-6 gene of the mitochondrial DNA. Hum Mol Genet 2001; 10:1221–1228.
50. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci USA 2001; 98:2284–2288.
51. Lam W, Chen C, Ruan S, Leung CH, Cheng YC. Expression of deoxynucleotide carrier is not associated with the mitochondrial DNA depletion caused by anti-HIV dideoxynucleoside analogs and mitochondrial dNTP uptake. Mol Pharmacol 2005; 67:408–416.
52. Lewis W, Haase CP, Miller YK, Ferguson B, Stuart T, Ludaway T, et al. Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS. Lab Invest 2005; 85:972–981.
53. Hirano M, Lagier-Tourenne C, Valentino ML, Marti R, Nishigaki Y. Thymidine phosphorylase mutations cause instability of mitochondrial DNA. Gene 2005; 18:152–156.
54. Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, et al. Maternal–fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48:4332–4336.
55. Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS 2005; 19:1341–1349.
© 2006 Lippincott Williams & Wilkins, Inc.